Top-down Infliximab Study in Kids With Crohn's Disease
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a top-down treatment approach, prescribing
infliximab (IFX) and azathioprine (AZA) at diagnose, yields better outcome in comparison to
the usual step-up treatment approach, starting with prednison and AZA or exclusive enteral
nutrition (EEN) and AZA, in moderate-to-severe pediatric Crohn's disease (CD) patients.
Phase:
Phase 4
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer ZonMw: The Netherlands Organisation for Health Research and Development